A study titled “Association Between Semaglutide and Risk of Bone Fractures in Type 2 Diabetes” was presented at the Endocrine Society’s ENDO 2026 Annual Meeting in Chicago by co-authors Jairo Noreña Velasquez, MD; William C. Pike, MD; Gavin Hui, MD; Yasaman Motlaghzadeh, MD, MPH; Julie Chen, MD; Deborah E. Sellmeyer, MD; Joy Y. Wu, MD, PhD; and Dr. Sun Kim, Associate Professor at Stanford University School of Medicine. The authors are affiliated with Stanford University Medical Center, Stanford University School of Medicine, Alameda Health System, and Atropos Health.
Short Summary:
Concerns regarding the potential link between GLP-1 weight-loss interventions and accelerated bone loss have been growing, particularly for individuals with type 2 diabetes.
This study evaluated the association between Semaglutide use and fracture incidence in patients with type 2 diabetes. The findings provide some reassurance and suggest that not all GLP-1 medications have the same effects. Semaglutide was associated with a 15% reduction in fracture incidence compared to an alternative GLP-1 therapy and other weight-loss treatments, despite greater weight loss observed in the Semaglutide group.